FDA Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) for Subcutaneous Use in Adult Solid Tumors
Bristol Myers Squibb has received FDA approval for Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use. This innovative product is a combination of nivolumab and recombinant human hyaluronidase (rHuPH20). It is now approved for most adult solid tumor indications where Opdivo is used, including monotherapy, maintenance therapy post-Opdivo plus Yervoy® (ipilimumab), or in combination with chemotherapy or cabozantinib. This approval follows the Phase III CheckMate-67T trial, demonstrating comparable efficacy, safety, and pharma...
